Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Bristol-Myers Squibb | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Bristol-Myers Squibb

Revenue growth in the quarter primarily driven by Celgene acquisition

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Bristol-Myers Squibb

4Q Revenues: $7.9 billion (+33%)

4Q Loss: $1.1 billion (earnings were $1.2 billion 4Q18)

FY Revenues: $26.1 billion (+16%)

FY Earnings: $3.4 billion (-30%)

Comments: Eliquis sales were $2.0 billion in the quarter, up 19%. Opdivo sales were $1.8 billion, down 2%. Orencia sales were $792 million in the quarter, up 8%. Sprycel sales were up 2% to $549 million. Yervoy sales were flat at $385 million. Top selling Celgene products include: Revlimid with sales of $1.3 billion, Pomalyst/Imnovid with $322 million in sales, and Abraxane with $166 million in sales. Revenue growth was primarily due to the Celgene acquisition (closed on November 20, 2019). In connection with the regulatory approval process of the acquisition, Celgene entered into an agreement to divest the global rights to Otezla to Amgen Inc. for $13.4 billion in cash. Research and development expenses increased 52% to $2.1 billion in the quarter primarily due $500 million related to the Celgene acquisition. Marketing, selling and administrative expenses increased 30% to $1.7 billion in the quarter primarily due to $400 million costs associated with the Celgene acquisition.

 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters